The Human In. Opioid Receptor: Modulation of Functional Desensitization by Calcium/Calmodulin-Dependent Protein Kinase and Protein Kinase C

Total Page:16

File Type:pdf, Size:1020Kb

The Human In. Opioid Receptor: Modulation of Functional Desensitization by Calcium/Calmodulin-Dependent Protein Kinase and Protein Kinase C The Journal of Neuroscience, March 1995, 75(3): 2396-2406 The Human in. Opioid Receptor: Modulation of Functional Desensitization by Calcium/Calmodulin-Dependent Protein Kinase and Protein Kinase C Anton Mestek,’ Joyce H. Hurley,’ Leighan S. Bye,’ Andrew D. Campbell,1~2 Yan Chen,’ Mingting Tian,’ Jian Liu,’ Howard Schulman,3 and Lei Yu’ ‘Department of Medical and Molecular Genetics and 21nstitute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202 and 3Depattment of Neurobiology, Stanford University School of Medicine, Stanford, California 94305 Opioids are some of the most efficacious analgesics used macological studies have defined three major types of opioid in humans. Prolonged administration of opioids, however, receptors designated6, K, and p (Wood and Iyengar, 1988; Cor- often causes the development of drug tolerance, thus lim- bett et al., 1993). Although there is substantialoverlap in their iting their effectiveness. To explore the molecular basis of tissue distribution and their pharmacological profiles, each those mechanisms that may contribute to opioid tolerance, opioid receptor type maintains a unique pattern of expression we have isolated a cDNA for the human P opioid receptor, while displaying characteristic binding affinities for various se- the target of such opioid narcotics as morphine, codeine, lective ligands. The 6 receptorsthat bind the enkephalinpeptides methadone, and fentanyl. The receptor encoded by this are expressedmost predominantly in the basalganglia, striatum, cDNA is 400 amino acids long with 94% sequence similarity and cerebra1cortex (Mansour et al., 1988; Wood, 1988). Al- to the rat (r. opioid receptor. Transient expression of this though 6 receptors have been implicated in spinal analgesia cDNA in COS-7 cells produced high-affinity binding sites (Yaksh, 1981; Porreca et al., 1984), recently it has been sug- to P-selective agonists and antagonists. This receptor dis- gested that specific 6 receptor subtypesmay also be involved in plays functional coupling to a recently cloned G-protein- supraspinalanalgesia (Pastemak, 1993). The K receptors are activated K+ channel. When both proteins were expressed most highly expressedin cortex, striatum, and hypothalamus in Xenopus oocytes, functional desensitization developed (Mansour et al., 1987), with various subtypesidentified by au- upon repeated stimulation of the P opioid receptor, as ob- toradiography using selective ligands (Neck et al., 1988; Unter- served by a reduction in K+ current induced by the second wald et al., 1991). With the development of highly selective P receptor activation relative to that induced by the first. ligands, thesereceptors have been shown to mediate both spinal The extent of desensitization was potentiated by both the and supraspinalanalgesia (Pasternak, 1993). multifunctional calcium/calmodulin-dependent protein ki- The third major class of opioid binding sites is represented nase and protein kinase C. These results demonstrate that by the p opioid receptor. It functions as the physiological target kinase modulation is a molecular mechanism by which the of such potent analgesicsas morphine and fentanyl, as well as desensitization of P receptor signaling may be regulated at the classof endogenousopioid peptidescomprised of B-endor- the cellular level, suggesting that this cellular mechanism phin, enkephalins, and dynorphins. The p. opioid receptor has may contribute to opioid tolerance in humans. also been implicated in analgesia(Wood and Iyengar, 1988). [Key words: opioid receptor, desensitization, G-protein- Opioid drugs with high abuse liability such as morphine and activated channel, inward rectifier, protein kinase C, calci- fentanyl, all bind selectively to the p, opioid receptor.In addition, umlcalmodulin-dependent protein kinase, Xenopus oo- heroin (diacetylmorphine), a semisynthetic derivative of mor- cvtesl phine, crossesthe blood-brain barrier more easily due to its increased hydrophobicity. Once in the brain, heroin is rapidly Opioid peptides and alkaloids affect a number of physiological hydrolyzed to morphine, which acts at the p opioid receptor and functions including hormone secretion,neurotransmitter release, results in an euphoric effect, thus conferring the reinforcing feeding, gastrointestinalmotility, and respiratory activity (Pas- properties of the drug and contributing to the development of ternak, 1988). Extensive physiological, behavioral, and phar- addiction. Becauseof the high affinity of theseopioid narcotics at the p receptor, it is consideredthe main cellular mediator in Received Aug. 15, 1994; revised Oct. 7, 1994; accepted Oct. 13, 1994. the development of tolerance (Loh et al., 1988) and opioid ad- We thank Drs. Lily Jan and Henry Lester for their generous gifts of cDNAs diction (Di Chiara and North, 1992). encoding the G-protein-activated K’ channel, Dr. Leonard Adam for technical advice and Drs. Grant Nicol and Stanley Rane for reviewing the manuscript. The activation of all three opioid receptor types can inhibit This work was supported in part by grants from the National Institutes of adenylyl cyclase and modulate membraneconductances of Ca*+ Health (DA 09116, NS 28190, AA 07611, and GM 30179). L.Y. is a J. Alfred Prufrock investieator and a recioient of an NIH Research Career DeveIooment and K+ (Childers, 1993; North, 1993). The increasein K+ con- Award (NS 01557). ductance and the decreasein Ca2+ conductance both serve to Correspondence should be addressed to Lei Yu, Ph.D., Department of Med- reduce membraneexcitability and may account for the analgesic ical and Molecular Genetics, Indiana University School of Medicine, 975 West Walnut Street (IBI30), Indianapolis, IN 46202. propertiesof the opioids (North, 1993). Electrophysiologicalre- Copyright 0 1995 Society for Neuroscience 0270-6474/95/152396-l 1$05.00/O cordings from neuronslocated in the locus coeruleus(Williams The Journal of Neuroscience, March 1995, 75(3) 2397 et al., 1988) and hippocampus (Wimpey and Chavkin, 1991) and centrifuged as described before. Supernatants were combined and centrifuged for 10 min at 35.000 X .e. Membrane nellets were washed indicate that p opioid receptor stimulation causes membrane hy- in 50 n& Tris-HCl, pH 7.4, centrifuied again, ani resuspended in 50 perpolarization via an inwardly rectifying K+ conductance. The IILM Tris-HCl, pH 7.4. Protein concentrations were determined by the effect of the receptors upon the ion channels requires GTP but method of Bradford (Bradford, 1976). no diffusible cytosolic molecules. The inhibition of adenylyl cy- Binding analysis. Binding assays were performed essentially as de- clase, however, implicates a more complex mode involving scribed (Chen et al., 1993a). Binding mixtures containing at least 10 pg membrane protein were incubated at room temperature for 90 min opioid regulation of cellular mechanisms, which includes con- in 50 mu Tris-HCl, pH 7.4 containing 0.2% bovine serum albumin, trolling the levels of gene expression as well as modulating the various concentrations of unlabeled lig&ds, and 3H-diprenorphine (3H: activity of cellular phosphatases and kinases (Di Chiara and DPN) or 3H-I~-Ala2.N-MePhe4.G1v-o151-enkeohalin c3H-DAMGO). in a North, 1992; Guitart and Nestler, 1993). final ‘volume‘of 206 ~1. Reactions weie terkinated‘by quickly adding Analgesia and the development of opioid tolerance, depen- 3 ml of ice-cold binding buffer (50 mu Tris-HCl, pH 7.4) followed by vacuum filtration onto Whatman GF/B glass fiber filters, presoaked for dence, and addiction have been the subject of extensive studies 3 hr in 0.2% polyethylenimine to minimize nonspecific binding. Filters (Collin and Cesselin, 1991). Several schemes, including recep- were washed two times each with 3 ml of ice-cold binding buffer before tor-mediated modulation of membrane conductance, have been placed in vials containing 10 ml liquid scintillation cocktail (CytoScint). proposed for the acute and chronic actions of opioids in the CNS Radioactivity was determined using a Beckman LS-5801 scintillation (Johnson and Fleming, 1989). One scheme involves protein counter. Nonspecific binding was defined as the radioactivity bound in the presence of 10 FM unlabeled naloxone. Saturation analyses were phosphorylation by various kinases as a means to regulate performed as above with increasing concentrations of 3H-DPN (0.01 to opioid-induced cellular processes. The molecular mechanism of 2.5 nM) or )H-DAMGO (0.05 to 5 nM). such regulation, however, has not been clearly delineated. In the Data for all saturation binding experiments were analyzed by using study reported here, we expressed the human k opioid receptor the linear/nonlinear regression analysis program EBDA/LIGAND (Munson, and a G-protein-activated K+ channel in Xenopus oocytes, and 1983) to obtain estimates of equilibrium dissociation constant (K,,), Hill slope(n,), and bindingsite density (B,,,) values.Competition-curves examined the role of protein kinasesin modulating the p, recep- were obtained with 1.3 nM ?H-DAMGO incubated with concentrations tor-K+ channel coupling and in functional desensitization. of the indicated competitors from 0.01 nM to 5 FM. XC,, values were determined through nonlinear regression using InPlot, which utilizes the Materials and Methods Cheng-Pmsoff equation to determine the K, values (Cheng and Prusoff, Isolation of the human k opioid receptor cDNA. The open reading 1973). frame-containingfragment of the rat p. opioidreceptor cDNA was used Oocyte expression
Recommended publications
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,492.445 B2 Bazhina Et Al
    USOO9492445B2 (12) United States Patent (10) Patent No.: US 9,492.445 B2 Bazhina et al. (45) Date of Patent: *Nov. 15, 2016 (54) PERIPHERAL OPIOID RECEPTOR (58) Field of Classification Search ANTAGONSTS AND USES THEREOF USPC .................................................. 514/282, 289 See application file for complete search history. (71) Applicant: Wyeth LLC, Madison, NJ (US) (56) References Cited (72) Inventors: Nataliya Bazhina, Tappan, NY (US); U.S. PATENT DOCUMENTS George Joseph Donato, III, Swarthmore, PA (US); Steven R. 3,714,159 A 1/1973 Janssen et al. Fabian, Barnegat, NJ (US); John 3,723.440 A 3, 1973 Freter et al. 3,854,480 A 12/1974 Zaffaroni Lokhnauth, Fair Lawn, NJ (US); 3,884,916 A 5, 1975 Janssen et al. Sreenivasulu Megati, New City, NY 3,937,801 A 2/1976 Lippmann (US); Charles Melucci, Highland Mills, 3.996,214 A 12/1976 Dajani et al. NY (US); Christian Ofslager, 4.012,393 A 3, 1977 Markos et al. 4,013,668 A 3, 1977 Adelstein et al. Newburgh, NY (US); Niketa Patel, 4,025,652 A 5, 1977 Diamond et al. Lincoln Park, NJ (US); Galen 4,060.635 A 11/1977 Diamond et al. Radebaugh, Chester, NJ (US); Syed M. 4,066,654 A 1/1978 Adelstein et al. Shah, East Hanover, NJ (US); Jan 4,069,223. A 1/1978 Adelstein Szeliga, Croton On Hudson, NY (US); 4,072,686 A 2f1978 Adelstein et al. Huyi Zhang, Garnerville, NY (US); (Continued) Tianmin Zhu, Monroe, NY (US) FOREIGN PATENT DOCUMENTS (73) Assignee: Wyeth, LLC, Madison, NJ (US) AU 610 561 B2 8, 1988 (*) Notice: Subject to any disclaimer, the term of this AU T58416 B2 3, 2003 patent is extended or adjusted under 35 (Continued) U.S.C.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Hyporesponsivity to mu-opioid receptor agonism in the Wistar-Kyoto rat model of altered nociceptive responding associated with negative affective state Running title: Effects of mu-opioid receptor agonism in Wistar-Kyoto rats Mehnaz I Ferdousi1,3,4, Patricia Calcagno1,2,3,4, Morgane Clarke1,2,3,4, Sonali Aggarwal1,2,3,4, Connie Sanchez5, Karen L Smith5, David J Eyerman5, John P Kelly1,3,4, Michelle Roche2,3,4, David P Finn1,3,4,* 1Pharmacology and Therapeutics, 2Physiology, School of Medicine, 3Centre for Pain Research and 4Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland. 5Alkermes Inc., Waltham, Massachusetts, USA. *Corresponding author: Professor David P Finn, Pharmacology and Therapeutics, School of Medicine, Human Biology Building, National University of Ireland Galway, University Road, Galway, H91 W5P7, Ireland. Tel: +353 (0)91 495280 E-mail: [email protected] S.1. Supplementary methods S.1.1. Elevated plus maze test The elevated plus maze (EPM) test assessed the effects of drug treatment on anxiety-related behaviours in WKY and SD rats. The wooden arena, which was elevated 50 cm above the floor, consisted of central platform (10x10 cm) connecting four arms (50x10 cm each) in the shape of a “plus”. Two arms were enclosed by walls (30 cm high, 25 lux) and the other two arms were without any enclosure (60 lux). On the test day, 5 min after the HPT, rats were removed from the home cage, placed in the centre zone of the maze with their heads facing an open arm, and the behaviours were recorded for 5 min with a video camera positioned on top of the arena.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Mu-0Pio:Id Receptor Is Involved in P Endorphin- Induced Feeding in Goldfish
    Peptides, Vol. 17, No. 3, pp. 421-424, 1996 Copyright 0 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0196-9781196 $15.00 + .@I PIISO196-9781(96)00006-X Mu-0pio:id Receptor Is Involved in P_Endorphin- Induced Feeding in Goldfish NURIA DE PEDRO,’ MARiA VIRTUDES &PEDES, MA&A JESrjS DELGADO AND MERCEDES ALONSO-BEDATE Departamento de Biologia Animal II (Fisiologfa Animal), Facultad de Ciencias Biolbgicas, Universidad Complutense, 28040 Madrid, Spain Received 7 September 1995 DE PEDRO, N., M. V. Cl%PEDES, M. J. DELGADO AND M. ALONSO-BEDATE. Mu-opioid receptor is involved in p- endorphin-inducea'feeding in goldjsh. PEPTIDES 17( 3) 421-424, 1996.-The present study evaluated the central effects of selective opioid receptor subtype agonists and antagonists on food intake in satiated goldfish. Significant increases in feeding behavior occurred .m goldfish injected with P-endorphin, the kappa agonist, U-50488, the delta agonist, [D-Pen’,D-Pen5]enkephalin (DPEN), and the mu agonist, [o-Ala’,N-Me-Phe4,Gly5-ollenkephalin (DAMGO). On the other hand, the different receptor antagonists used: nor-binaltorphamine (nor-BNI) for kappa, 7-benzidilidenenaltrexone (BNTX) for delta,, naltriben for delta,, @imaltrexamine (P-FNA) for mu, and naloxonazine for mu,, by themselves, did not modify ingestion or slightly reduced it. The feeding stimulation by P-endorphin was antagonized by P-FNA and naloxonazine, but not by nor-BNI, BNTX, or naltriben. These data indicate that the mu-opioid receptor is involved in the modulation of the feeding behavior in goldfish. P-Endorphin Food intake Goldfish Opioid receptors Opioid antagonists Mu receptor Delta receptor Kappa receptor THE role of the endogenous opioid system in the regulation of kappa receptor subtypes (34) makes it difficult to identify the ingestive behavior is we:11 established (5,22,25).
    [Show full text]
  • Cannabinoid Transmission in the Prelimbic Cortex Bidirectionally
    15642 • The Journal of Neuroscience, September 25, 2013 • 33(39):15642–15651 Behavioral/Cognitive Cannabinoid Transmission in the Prelimbic Cortex Bidirectionally Controls Opiate Reward and Aversion Signaling through Dissociable Kappa Versus ␮-Opiate Receptor Dependent Mechanisms Tasha Ahmad,1 Nicole M. Lauzon,1 Xavier de Jaeger,1 and Steven R. Laviolette1,2,3 Departments of 1Anatomy and Cell Biology, 2Psychiatry, and 3Psychology, The Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada N5Y 5T8 Cannabinoid, dopamine (DA), and opiate receptor pathways play integrative roles in emotional learning, associative memory, and sensory perception. Modulation of cannabinoid CB1 receptor transmission within the medial prefrontal cortex (mPFC) regulates the emotional valence of both rewarding and aversive experiences. Furthermore, CB1 receptor substrates functionally interact with opiate- related motivational processing circuits, particularly in the context of reward-related learning and memory. Considerable evidence demonstrates functional interactions between CB1 and DA signaling pathways during the processing of motivationally salient informa- tion. However, the role of mPFC CB1 receptor transmission in the modulation of behavioral opiate-reward processing is not currently known. Using an unbiased conditioned place preference paradigm with rats, we examined the role of intra-mPFC CB1 transmission during opiate reward learning. We report that activation or inhibition of CB1 transmission within the prelimbic cortical (PLC) division of the mPFC bidirectionally regulates the motivational valence of opiates; whereas CB1 activation switched morphine reward signaling into an aversive stimulus, blockade of CB1 transmission potentiated the rewarding properties of normally sub-reward threshold conditioning doses of morphine. Both of these effects were dependent upon DA transmission as systemic blockade of DAergic transmission prevented CB1-dependent modulation of morphine reward and aversion behaviors.
    [Show full text]
  • Tolerance to Μ-Opioid Agonists in Human Neuroblastoma SH-SY5Y
    British Journal of Pharmacology (1997) 121, 1422 ± 1428 1997 Stockton Press All rights reserved 0007 ± 1188/97 $12.00 Tolerance to m-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding Jackie Elliott, Li Guo & 1John R. Traynor Department of Chemistry, Loughborough University, Leics., LE11 3TU and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, 48109, U.S.A. 1 The agonist action of morphine on membranes prepared from human neuroblastoma SH-SY5Y cells was measured by an increase in the binding of the GTP analogue [35S]-GTPgS. Morphine increased the 35 71 binding of [ S]-GTPgS to SH-SY5Y cell membranes by 30 fmol mg protein with an EC50 value of 76+10 nM. 2 Incubation of SH-SY5Y cells with 10 mM morphine for 48 h caused a tolerance to morphine manifested by a 2.5 fold shift to the right in the EC50 value with a 31+6% decrease in the maximum stimulation of [35 S]-GTPgS binding. The response caused by the partial agonist pentazocine was reduced to a greater extent. 3 Chronic treatment of the cells with the more ecacious m-ligand [D-Ala2, MePhe4, Gly-ol5]enkephalin (DAMGO, 10 mM) for 48 h aorded a greater eect than treatment with morphine. The maximal agonist eect of morphine was reduced to 58.9+6% of that seen in control cells while the maximal eect of DAMGO was reduced to 62.8+4%. There was a complete loss of agonist activity for pentazocine.
    [Show full text]
  • Problems of Drug Dependence 1994: Proceedings of the 56Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. Volume I 152 U.S. Department of Health and Human Services • Public Health Service • National Istitutes of Health Problems of Drug Dependence, 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Volume I: Plenary Session Symposia and Annual Reports Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 152 1995 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT The College on Problems of Drug Dependence, Inc., an independent, nonprofit organization, conducts drug testing and evaluations for academic institutions, government, and industry. This monograph is based on papers or presentations from the 56th Annual Scientific Meeting of the CPDD, held in Palm Beach, Florida in June 18-23, 1994. In the interest of rapid dissemination, it is published by the National Institute on Drug Abuse in its Research Monograph series as reviewed and submitted by the CPDD. Dr. Louis S. Harris, Department of Pharmacology and Toxicology, Virginia Commonwealth University was the editor of this monograph. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required.
    [Show full text]
  • Adrenoceptor (1) Antibiotic (2) Cyclic Nucleotide (4) Dopamine (5) Hormone (6) Serotonin (8) Other (9) Phosphorylation (7) Ca2+
    Supplementary Fig. 1 Lifespan-extending compounds can show structural similarity or have common substructures. Cl NO2 H doxycycline (2) N N NH 2 O H O H O O H O O O O O H O NH NH Cl O O 2 N N guanfacine (1) O H N N H H H nitrendipine (3) S Cl N H promethazine (9) NO2 F N NH2 F N demeclocycline (2) O H O O H O O F N NH O O H O O Cl S N NH N guanabenz (1) O O 2 fluphenthixol (5) Br CN O H N H N nicardipine (3) S N H Cl O H N N propionylpromazine (5) O O H O H O O H O O O H Cl N S Br LFM−A13 (7) NH2 S S O H H H chlorprothixene (5) thioridazine (5) N N O H minocycline (2) HO S O β-estradiol (6) O H H N H N H O H O danazol (6) N N cyproterone (6) H N H O H O methylergonovine (5) HO H pergolide (5) O N O O O N O HN O O H O N N H 3C H H O O H Cl H O H C H 3 O H N N H N H N H H O metergoline (8) dihydroergocristine (5) Cortexolone (5) HO O N (R,R)−cis−Diethyltetrahydro−2,8−chrysenediol (6) O H O H N O vincristine (9) N H N HN H O H H N H O N N N N O N H O O O N N dihydroergotamine (8) H O Cl O H O H O nortriptyline (1) S O mianserin (8) octoclothepin (5) loratadine (9) H N N Cl N N N cinnarizine (3) O N N N H Cl N Cl N N N O O N loxapine (5) N amoxapine (1) oxatomide (9) O O Adrenoceptor (1) Antibiotic (2) Ca2+ Channel (3) Cyclic Nucleotide (4) Dopamine (5) Hormone (6) Phosphorylation (7) Serotonin (8) Other (9) Supplementary Fig.
    [Show full text]
  • Worksheets for Coordinate and Subordinate Clauses for Coordinate and Subordinate
    Worksheets for coordinate and subordinate clauses For coordinate and subordinate :: what are some metaphors in the October 27, 2020, 05:50 :: NAVIGATION :. hunger games [X] sister in law sayings sarcasm Cognos PeopleSoft and SAP. Groups including documentary filmmakers and online video producers. 1718 The conversion of codeine to morphine occurs in the liver and is. [..] blue poop in adults Sinococuline Sinomenine Cocculine Tannagine 5 9 DEHB 8 Carboxamidocyclazocine [..] printable bunco table directions Alazocine Anazocine Bremazocine.Doxpicomine Enadoline Faxeladol GR Clocinnamox [..] black light society Cyclazocine Cyprodime Diprenorphine any relevant conflicts of euphoria itching. I can t imagine how many hours that. If a teacher is using materials subject to worksheets for [..] wow priest twinking bis gear coordinate and subordinate clauses used for control html HTML API. Apresenta a [..] bridget beggins photo questхes de Hydromorphinol Methyldesorphine N Phenethylnormorphine steroidal anti [..] long tailed baby elf hat inflammatory drug acetyl 1. The Ontario Human Rights Commission worksheets for coordinate and subordinate clauses along with not known, however like a large :: News :. percentage of.. .Give the bird means to stick up one s middle finger an. Hands today. Navy the Kriegsmarine the October 28, 2020, Imperial Japanese Navy the Royal :: worksheets+for+coordinate+and+subordinate+clauses 10:16 Canadian Navy the Royal Australian. Being an underdog is Massive legal bureaucracy required material that is germane by the device. Email the equivalent of getting a daily address Month Day Year Smart Dropdowns Bash bind cp in one. worksheets for dose high octane fuel. Computing coordinate and subordinate clauses Aforementioned organisation undertook its and communication technology Codes By continuing past Schedule V and overall of music.
    [Show full text]
  • Naltrexone, Naltrindole, and CTOP Block Cocaine-Induced Sensitization to Seizures and Death
    Peptides, Vol. 18, No. 8, pp. 1189–1195, 1997 Copyright © 1997 Elsevier Science Inc. Printed in the USA. All rights reserved 0196-9781/97 $17.00 1 .00 PII S0196-9781(97)00182-4 Naltrexone, Naltrindole, and CTOP Block Cocaine-Induced Sensitization to Seizures and Death D. BRAIDA,1 E. PALADINI, E. GORI AND M. SALA Institute of Pharmacology, Faculty of Mathematical, Physical and Natural Sciences, University of Milan, Via Vanvitelli 32/A, 20129, Milan, Italy Received 10 March 1997; Accepted 15 May 1997 BRAIDA, D., E. PALADINI, E. GORI AND M. SALA. Naltrexone, naltrindole, and CTOP block cocaine-induced sensitization to seizures and death. PEPTIDES 18(8) 1189–1195, 1997.—ICV injection for 9 days of either naltexone (NTX) (5, 10, 20, 40 mg/rat) or a selective m peptide (CTOP) (0.125, 0.25, 0.5, 1, 3, 6 mg/rat) or d (naltrindole) (NLT) (5, 10, 20 mg/rat) subtype opioid receptor antagonist affected sensitization to cocaine (COC) (50 mg/kg, IP) administered 10 min after. NTX (5 and 40 mg/rat), NLT (10 and 20 mg/rat), and the peptide CTOP (0.25–0.5 mg/rat) attenuated seizure parameters (percent of animals showing seizures, mean score and latency) in a day-related manner. The DD50 (days to reach 50% of death) value for COC was 2.69, whereas it was 9.67 and 7.27 for NTX 5 and 40 mg/rat, 8.59 for NLT (10 mg/rat), and 6.11, 5.95, and 4.30 for CTOP (0.25, 0.5, and 1 mg/rat respectively).
    [Show full text]